Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04674267 · ClinicalTrials.gov registry record · NA
Resilience and Equity in Aging, Cancer, and Health (REACH)
A NA study of Pancreatic Cancer and Gastric Cancer, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 257
- Enrollment target
- 1
- Study location
NCT04674267: Recruiting NA study of Pancreatic Cancer and Gastric Cancer, sponsored by Dana-Farber Cancer Institute.
NCT04674267 is a NA study of Pancreatic Cancer and Gastric Cancer that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 257 participants, below the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04674267, a NA study of Pancreatic Cancer and Gastric Cancer, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 257 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this multi-phase research study is to understand how consultation of cancer care with a geriatrician can best improve outcomes for older adults with gastrointestinal malignancies.
Primary Outcome
EFA questionnaire deployed to older adult patients age 70+ in the REACH study. Feasibility will be determined by the proportion of participants who consent to complete the electronic fitness assessment. The intervention will be considered feasible if 70% of participants consent to complete the fitness assessment.
Conditions Studied
Interventions
- OTHER Phase 2 Intervention - Geriatric Co-Management
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 257 participants |
| Start Date | 2022-01-18 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT04674267 shows while recruiting
NCT04674267 is an interventional study that assigns participants to a tested intervention. The registered 257 participants enrollment target is mid-sized for trials with a published cap, below the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (34% lower).
The record links to 6 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Phase 2 Intervention - Geriatric Co-Management is the first listed.
NCT04674267 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04674267 about?
NCT04674267 is a clinical study titled "Resilience and Equity in Aging, Cancer, and Health (REACH)". The purpose of this multi-phase research study is to understand how consultation of cancer care with a geriatrician can best improve outcomes for older adults with gastrointestinal malignancies.
What is the current status of trial NCT04674267?
This trial is currently recruiting. It is a NA study. The enrollment target is 257 participants. The study started on 2022-01-18. Estimated completion is 2026-12-31.
What conditions does trial NCT04674267 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Colon Cancer, Rectal Cancer.
What interventions are being tested in trial NCT04674267?
The interventions under investigation include: Phase 2 Intervention - Geriatric Co-Management (OTHER).
Who is sponsoring clinical trial NCT04674267?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04674267 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04674267's enrollment target sits among peer trials
257 57th of 278 higher than 222 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
RECRUITING · NA
-
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
RECRUITING · NA
-
Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)
RECRUITING · NA
-
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03618550 · 257 participants · Phase 2
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
- NCT06099288 · 257 participants · NA
Strong Families Start at Home/Familias Fuertes Comienzan en Casa
- NCT06207084 · 257 participants · NA
The Fit With Us Study
- NCT03785288 · 258 participants · Phase 3
Vaginal Cuff Brachytherapy Fractionation Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI